| 000 | 01798 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250511184630.0 | ||
| 264 | 0 | _c19921231 | |
| 008 | 199212s 0 0 eng d | ||
| 022 | _a0954-6820 | ||
| 024 | 7 |
_a10.1111/j.1365-2796.1992.tb00610.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aEvensen, S A | |
| 245 | 0 | 0 |
_aSurvival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy. _h[electronic resource] |
| 260 |
_bJournal of internal medicine _cNov 1992 |
||
| 300 |
_a433-7 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aActuarial Analysis |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAmsacrine _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 | _aBone Marrow Examination |
| 650 | 0 | 4 | _aBone Marrow Transplantation |
| 650 | 0 | 4 | _aCause of Death |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 |
_aDaunorubicin _xadministration & dosage |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xclassification |
| 650 | 0 | 4 | _aLeukocyte Count |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNorway _xepidemiology |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThioguanine _xadministration & dosage |
| 700 | 1 | _aBrinch, L | |
| 700 | 1 | _aStavem, P | |
| 700 | 1 | _aTjønnfjord, G | |
| 773 | 0 |
_tJournal of internal medicine _gvol. 232 _gno. 5 _gp. 433-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2796.1992.tb00610.x _zAvailable from publisher's website |
| 999 |
_c1459617 _d1459617 |
||